Apigenin is a promising molecule for treatment of visceral leishmaniasis
Frontiers in Cellular and Infection Microbiology · 05.04.2023 · 13
DOI: 10.3389/fcimb.2023.1066407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 05.04.2023. Verfasst von Yago S S Emiliano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Bioquímica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz - FIOCRUZ, Rio de Janeiro, RJ, Brazil. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Leishmania infantum, Antiprotozoal Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Oswaldo Cruz.
Abstract (Originalsprache)
Current treatment for visceral leishmaniasis is based on drugs such as pentavalent antimony and amphotericin B. However, this treatment remains mostly ineffective and expensive, resulting in several side effects and generating resistance. Apigenin, a flavonoid present in fruits and vegetables, has demonstrated several biological functions. In the present study, we observed a concentration-dependent inhibition of the L. infantum promastigote in the presence of apigenin, exhibiting an IC 50 value of 29.9 µM. Its effect was also evaluated in L. infantum -infected murine peritoneal macrophages, presenting an C 50 value against intracellular amastigotes of 2.3 µM and a selectivity index of 34.3. In a murine model of visceral leishmaniasis, the in vivo effect of apigenin was measured using short-term and long-term treatment schemes. Treatment with apigenin demonstrated 99.7% and 94% reductions in the liver parasite load in the short-term and long-term treatment schemes, respectively. Furthermore, no alterations in serological and hematological parameters were observed. Taken together, these results suggest that apigenin is a potential candidate for visceral leishmaniasis chemotherapy by oral administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Bioquímica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
Förderung
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Oswaldo Cruz
Zitieren
APA
Emiliano, Y. S. S., & Almeida-Amaral, E. E. (2023). Apigenin is a promising molecule for treatment of visceral leishmaniasis. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1066407
Vancouver
Emiliano YSS, Almeida-Amaral EE. Apigenin is a promising molecule for treatment of visceral leishmaniasis. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1066407
BibTeX
@article{Emiliano2023,
author = {Emiliano, Yago S S and Almeida-Amaral, Elmo E},
title = {Apigenin is a promising molecule for treatment of visceral leishmaniasis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1066407}
}
EUVIMED